CF
ALLO icon

Crosspoint Financial’s Allogene Therapeutics ALLO Stock Holding History

Crosspoint Financial’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-12,000
Closed -$38.5K – 14
2023
Q4 		$38.5K Hold
12,000
– – 0.38% 10
2023
Q3 		$38K Hold
12,000
– – 0.4% 8
2023
Q2 		$59.6K Buy
+12,000
New +$64.9K 0.61% 9

Other funds holding ALLO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Crosspoint Financial's ALLO Position: Q1 2024 in Review

Crosspoint Financial sold out of Allogene Therapeutics (ALLO) in Q1 2024, closing a stake of 12,000 shares — an estimated $38.5K sold.

Crosspoint Financial first reported a position in ALLO in Q2 2023 and held it in 3 quarters. The position peaked at $59.6K in Q2 2023. 161 funds tracked by Wall St. Rank hold ALLO as of Q1 2024.

  • Crosspoint Financial reported no remaining Allogene Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Crosspoint Financial sold 12,000 Allogene Therapeutics shares in Q1 2024, an estimated $38.5K.
  • Crosspoint Financial first reported a position in Allogene Therapeutics in Q2 2023 and held it in 3 quarters.
  • Crosspoint Financial's Allogene Therapeutics position peaked at $59.6K in Q2 2023.
  • 161 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2024.

Based on Crosspoint Financial's 13F filing for Q1 2024, filed 24 Apr 2024.